Addition of canagliflozin to insulin improves glycemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial
Diabetes, Obesity and Metabolism May 19, 2019
Torimoto K, et al. - In type 2 diabetes (T2D), researchers assessed the effectiveness of canagliflozin in decreasing the required insulin dose and the risk of hypoglycemia. For this randomized controlled trial, patients with T2D treated with insulin were randomly assigned to the control (n=17) or the canagliflozin (n=17, plus 100 mg/day canagliflozin) group. In the canagliflozin vs the control group, change from baseline in daily insulin dose was significantly smaller. In the control group, low blood glucose index and predicted % of blood glucose (BG) <70 mg/dL, both hypoglycemia-related parameters, got significantly worse, but stayed unchanged in the canagliflozin group. Only in the canagliflozin group, the standard deviation (SD) for nighttime BG levels improved significantly. In patients with T2D, supplementing insulin therapy with 100 mg canagliflozin lowered the required dose of insulin and hypoglycemic risk and leveled out glycemic fluctuations at night while sustaining the same glycemic control level.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries